Institution
Medisch Spectrum Twente
Healthcare•Enschede, Netherlands•
About: Medisch Spectrum Twente is a healthcare organization based out in Enschede, Netherlands. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 1371 authors who have published 2508 publications receiving 84008 citations. The organization is also known as: MST & Medisch Spectrum Twente Koningsplein.
Papers published on a yearly basis
Papers
More filters
••
Broad Institute1, Harvard University2, Monash University3, Kyoto University4, Genentech5, Vanderbilt University6, New York University7, NewYork–Presbyterian Hospital8, Second Military Medical University9, University of Queensland10, University of Toronto11, University of Groningen12, University of Tartu13, Beijing Jiaotong University14, Icahn School of Medicine at Mount Sinai15, Radboud University Nijmegen16, Medisch Spectrum Twente17, Leiden University18, University of Paris19, French Institute of Health and Medical Research20, University of Alabama at Birmingham21, GlaxoSmithKline22, University of Amsterdam23, University of Cambridge24, Hanyang University25, Spanish National Research Council26, Complutense University of Madrid27, Umeå University28, Boston University29, Council on Education for Public Health30, McGill University31, University of Manchester32, National Health Service33, University of Pittsburgh34, University of California, San Francisco35, Karolinska Institutet36, North Shore-LIJ Health System37, University of Chicago38, University of Tokyo39
TL;DR: A genome-wide association study meta-analysis in a total of >100,000 subjects of European and Asian ancestries provides empirical evidence that the genetics of RA can provide important information for drug discovery, and sheds light on fundamental genes, pathways and cell types that contribute to RA pathogenesis.
Abstract: A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological data sets to provide insight into disease pathogenesis and guide drug discovery for complex traits such as rheumatoid arthritis (RA)1. Here we performed a genome-wide association study meta-analysis in a total of >100,000 subjects of European and Asian ancestries (29,880 RA cases and 73,758 controls), by evaluating ~10 million single-nucleotide polymorphisms. We discovered 42 novel RA risk loci at a genome-wide level of significance, bringing the total to 101 (refs 2, 3, 4). We devised an in silico pipeline using established bioinformatics methods based on functional annotation5, cis-acting expression quantitative trait loci6 and pathway analyses7, 8, 9—as well as novel methods based on genetic overlap with human primary immunodeficiency, haematological cancer somatic mutations and knockout mouse phenotypes—to identify 98 biological candidate genes at these 101 risk loci. We demonstrate that these genes are the targets of approved therapies for RA, and further suggest that drugs approved for other indications may be repurposed for the treatment of RA. Together, this comprehensive genetic study sheds light on fundamental genes, pathways and cell types that contribute to RA pathogenesis, and provides empirical evidence that the genetics of RA can provide important information for drug discovery.
1,910 citations
••
TL;DR: In this article, the authors did a multicentre prospective randomised trial to find whether postoperative pelvic radiotherapy improves locoregional control and survival for patients with stage-1 endometrial carcinoma.
1,503 citations
••
TL;DR: This combined-therapy regimen offers additional disease control over and above that of sulphasalazine alone that persists for up to a year after corticosteroids are stopped.
1,098 citations
••
TL;DR: VBT is effective in ensuring vaginal control, with fewer gastrointestinal toxic effects than with EBRT, and should be the adjuvant treatment of choice for patients with endometrial carcinoma of high-intermediate risk.
931 citations
••
TL;DR: This review outlines the main stages of the apoptotic cascade together with current FCM methods and states that all FCM apoptosis assays described have a solid experimental basis and have been used successfully in basic research on molecular and biochemical mechanisms of apoptosis.
755 citations
Authors
Showing all 1374 results
Name | H-index | Papers | Citations |
---|---|---|---|
Pim van der Harst | 99 | 517 | 42777 |
Robbert Sanderman | 72 | 405 | 20045 |
Jürgen Hescheler | 66 | 366 | 15279 |
Michel Henry-Amar | 64 | 219 | 11516 |
Roel Willemze | 55 | 143 | 12421 |
Hans A. Valkenburg | 53 | 115 | 13804 |
Johannes J. Rasker | 53 | 281 | 9870 |
Ingemar S. J. Merkies | 52 | 167 | 9089 |
Mart A F J van de Laar | 48 | 211 | 9972 |
Sophia E. de Rooij | 48 | 218 | 9408 |
Evelyn M. Monninkhof | 48 | 148 | 8416 |
Albertus Beishuizen | 47 | 178 | 8585 |
Erik Taal | 47 | 198 | 8153 |
J.H. Frederik Falkenburg | 45 | 190 | 6989 |
Cornelis B. Lambalk | 43 | 159 | 7233 |